Assessment of quality of life (QoL) using Skindex-16 in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with vismodegib (VISMO) in the STEVIE study - 21/04/16
Jean-Jacques Grob, Timone Hospital, Marseille, France; Karen Bartley, Genentech, Inc, South San Francisco, CA, United States; Rainer Kuntsfeld, Medical University of Vienna, Vienna, Austria; Brigitte Dréno, CHRU Hotel Dieu, Nantes Cedex 01, France; Laurent Mortier, University of Lille 2, Lille, France; Paolo Antonio Ascierto, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy; Caroline Dutriaux, Bordeaux University Hospital, Bordeaux Cedex, France; Nicolas Meyer, Paul Sabatier University and Toulouse Cancer University Institute, Toulouse, France; Bernard Guillot, University Hospital of Montpellier, Montpellier, France; Reinhard Dummer, University Hospital Zurich, Zurich, Switzerland
Sarah Williams,11 Alberto Fittipaldo,11 D. Scott Ernst,12 Axel Hauschild,13 Nicole Basset-Seguin,14 Johan Hansson15 11Roche Products Ltd, Welwyn Garden City, UK; 12Western Univ; London Regional Cancer Program, London, Ontario, Canada; 13Univ Hospital Schleswig-Holstein, Kiel, Germany; 14Univ Paris 7 & Hôpital Saint-Louis, Paris, France; 15Karolinska Institutet, Stockholm, Sweden
Le texte complet de cet article est disponible en PDF.| Supported by F. Hoffman-LaRoche. |
Vol 74 - N° 5S1
P. AB193 - mai 2016 Retour au numéro
Article précédent
- An overview of the skin surveillance and photoprotection behaviors in the liver transplant recipients in Queensland, Australia
- Baseline quality of life and psychosocial health of skin cancer patients
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?